Expert Interview
Second View: Discussing Pfizer's Phase 3 results for BRAFTOVI in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
Ticker(s): PFEInstitution: Duke University
- Instructor of Medical Oncology at Duke who treats gastrointestinal cancers and conducts research on tumor immunology and immunotherapy, particularly for melanoma and gastrointestinal malignancies.
- Laboratory and translational research is focused on tumor immune evasion and immunotherapy resistances, and the development of biomarkers with a specific interest in dendritic cell tolerance.
- Research and clinical goal of finding new immunotherapeutic options for patients with supportive biomarkers to identify patients.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
